Vanda Pharmaceuticals Inc (VNDA)
5.11
+0.14
(+2.82%)
USD |
NASDAQ |
Apr 19, 16:00
5.115
0.00 (0.00%)
Pre-Market: 20:00
Vanda Pharmaceuticals Revenue (TTM): 192.64M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 192.64M |
| September 30, 2023 | 211.85M |
| June 30, 2023 | 238.35M |
| March 31, 2023 | 256.69M |
| December 31, 2022 | 254.38M |
| September 30, 2022 | 257.92M |
| June 30, 2022 | 262.70M |
| March 31, 2022 | 266.20M |
| December 31, 2021 | 268.68M |
| September 30, 2021 | 268.32M |
| June 30, 2021 | 258.53M |
| March 31, 2021 | 252.84M |
| December 31, 2020 | 248.17M |
| September 30, 2020 | 241.44M |
| June 30, 2020 | 240.62M |
| March 31, 2020 | 237.48M |
| December 31, 2019 | 227.19M |
| September 30, 2019 | 219.30M |
| June 30, 2019 | 208.95M |
| March 31, 2019 | 197.24M |
| December 31, 2018 | 193.12M |
| September 30, 2018 | 184.35M |
| June 30, 2018 | 176.55M |
| March 31, 2018 | 171.26M |
| December 31, 2017 | 165.08M |
| Date | Value |
|---|---|
| September 30, 2017 | 159.05M |
| June 30, 2017 | 156.20M |
| March 31, 2017 | 150.17M |
| December 31, 2016 | 146.02M |
| September 30, 2016 | 139.62M |
| June 30, 2016 | 129.48M |
| March 31, 2016 | 121.04M |
| December 31, 2015 | 109.92M |
| September 30, 2015 | 93.44M |
| June 30, 2015 | 79.88M |
| March 31, 2015 | 63.16M |
| December 31, 2014 | 50.16M |
| September 30, 2014 | 43.57M |
| June 30, 2014 | 37.50M |
| March 31, 2014 | 34.95M |
| December 31, 2013 | 33.88M |
| September 30, 2013 | 33.02M |
| June 30, 2013 | 32.60M |
| March 31, 2013 | 32.65M |
| December 31, 2012 | 32.73M |
| September 30, 2012 | 33.18M |
| June 30, 2012 | 32.86M |
| March 31, 2012 | 31.91M |
| December 31, 2011 | 31.27M |
| September 30, 2011 | 30.16M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
192.64M
Minimum
Dec 2023
268.68M
Maximum
Dec 2021
242.75M
Average
248.17M
Median
Dec 2020
Revenue (TTM) Benchmarks
| ADMA Biologics Inc | 258.22M |
| INVO Bioscience Inc | 3.021M |
| Johnson & Johnson | 89.66B |
| Nektar Therapeutics | 90.12M |
| Invivyd Inc | -- |